ECP 2017 - Abstract Book

Objective:

Thymomas, the most common neoplasms of the anterior medi-

astinum, can invade the adjacent structures. But the endobronchial growth of

a thymoma and its diagnosis by bronchoscopic biopsy is rare.

Method:

Sixty-one years old male presented with cough. The CT scan

revealed a large mass lesion in anterior mediastinum invading right upper

and middle lobes of lung, and pericardium. On bronchoscopic examination

there were irregularities on respiratory mucosa of bronchi of right upper and

middle lobes. Microscopically, beneath the intact respiratory epithelium, a

biphasic tumour composed of epitheloid cells and lymphocytes was seen.

Eosinophilic abundant cytoplasm , centrally located nucleus with mild atypia

and syncytial growth pattern were remarkable features of the epitheloid cells

of this proliferation. The epitheloid cells were positive for pankeratin, p40,

pax-8, but negative for TTF1. The small cells resembling lymphocytes were

positive for tdt, CD5 and other T lymphocyte markers, but negative for

keratins and neuroendocrine markers .

Results:

Final diagnosis was invasive thymoma with features suggestive of

type B2.

Conclusion:

Thymoma should be considered when a biphasic prolifera-

tion of epitheloid cells and small lymphocytes is represented on a bron-

choscopic biopsy.

PS-24-002

PD1 and PD-L1 expression in thymic lesions

E. Kilic Bagir

, A. Acikalin, A. Avci, D. Gümürdülü, S. Paydas

Cukurova University, Faculty of Medicine, Dept. of Pathology, Adana,

Turkey

Objective:

Programmed death-ligand 1 (PD-L1) and Programmed death

1 (PD-1) expression has been shown in various tumours. In present study,

we aimed to search the relationship of PD-1/PDL-1 expression with path-

ologic and clinical features in thymic neoplasms and thymic hyperplasia

cases.

Method:

Fifty-two cases with thymic neoplasms (

= 44) and thymic hyper-

plasia (

= 8) were included in the study. Cases were reevaluated in terms of

demographic, clinical and histopathologic features. Immunohistochemically,

PD-1 and PDL-1 antibodies were performed.

Results:

Twenty-nine cases were male, 23 were female. Mean age was

45.2 (17

–

79 years). Most common histopathologic type was Thymoma

type AB (28.8 %), followed by thymic hyperplasia (15.4 %), type B1

thymoma (11.5 %), type B3 thymoma (11.5 %), thymic carcinoma

(11.5 %) and, type A thymoma (5.8 %), subsequently. Twenty-eight cases

(53.8 %) had Myastenia Gravis, diagnosed in last 1 year or before.

Immunohistochemically, no expression was detected by PD1 in thymic

hyperplasia (0/8), whereas expression was detected in 21 of 36 thymoma

cases, four of six thymic carcinoma cases. PD-L1 was expressed in 7 of 8

thymic hyperplasia, 31 of 36 thymoma, five of six thymic carcinoma

cases.

Conclusion:

Expression of PD1 in thymoma and thymic carcinoma cases

in thymic hyperplasia give rise to immunotherapy chance in unresectable,

metastatic and/or recurrent thymic neoplasm cases.

PS-25-001

High immunoexpression of EZH2 and SMYD3 in diagnostic prostate

biopsies independently predicts outcome in prostate cancer patients

J. Lobo

, Â. Rodrigues, L. Antunes, I. Graça, J. Ramalho-Carvalho, F.

Quintela-Vieira, A. T. Martins, J. Oliveira, C. Jerónimo, R. Henrique

IPO Porto, Dept. of Pathology, Portugal

Objective:

Overtreatment is a major concern in prostate cancer(PCa)

patients. Finding biomarkers that discriminate indolent from aggres-

sive disease is imperative. We aim to evaluate the prognostic value

of the immunoexpression of three epigenetic modifiers (EZH2,

LSD1 and SMYD3) in pre-therapeutic biopsies from a cohort of

PCa patients.

Method:

A consecutive series of 189 patients(1997

–

2001) diagnosed

with PCa by biopsy in a cancer center(IPO Porto) was selected. Follow-

up was last updated in November 2016. Biopsies were reviewed accord-

ing to most recent 2016 WHO criteria, including prognostic grade

groups(GG). Immunohistochemistry was assessed using digital image

analysis to increase consistency of results and cutoffs were determined

based on data distribution. Endpoints included disease-specific(DSS),

disease-free(DFS) and progression-free(PFS) survival.

Results:

High EZH2 and SMYD3 immunoexpression associated

with significantly worse DSS both in univariable analysis(HR

1.87, 95%CI 1.10

–

3.27; HR 2.68, 95%CI 1.02

–

7.92) and in multi-

variable analysis when adjusted for CAPRA score(HR 1.93, 95%CI

1.12

–

3.32; HR 2.71, 95%CI 1.04

–

7.10). In GG 1

–

3 patients, EZH2-

high cases displayed significantly worse DSS when adjusted for

patients

’

age and clinical stage (HR 3.66, 95%CI 1.15

–

11.60).

Conclusion:

High EZH2 and SMYD3 immunoexpression indepen-

dently predicts outcome at diagnosis in PCa patients when adjust-

ed for standard clinicopathological parameters. This might assist

clinicians in tailoring treatment options.

PS-25-002

PRMT1, useful immunohistochemical marker for distinguishing re-

nal oncocytoma and chromophobe renal cell carcinoma

J. Vjestica

, M. Bosic, M. Zivotic, S. Cirovic, D. Djordjevic, I. Vukovic,

A. Silva Luis, J. Markovic-Lipkovski, O. Hes

School of Medicine Belgrade, Dept. of Pathology, Serbia

Objective:

Distinguishing renal oncocytoma (RO) from chromophobe

renal cell carcinoma (chRCC) sometimes can be challenging. Protein

arginine methiltransferase 1 (PRMT1) expression has been observed in

malignancies. We investigated the potential utility of PRMT1 immuno-

histochemical positivity in differential diagnosis of RO and chRCC.

Method:

Tumour tissue was formalin fixed, paraffin embaded and stained

with hematoxylin and eosin. Immunohistochemical expression of PRMT1

was analyzed in 22 chRCCs and 15 RO. Nuclear immunohistochemical

PRMT1 positivity was considered as positive.

Results:

ROs showed PRMT1 immunohistochemical positivity in 11/

15(74 %) cases. ChRCCs expressed PRMT1in 9/22 (40 %) cases. The

significant statistical difference was proved (

= 0,012).

Conclusion:

PRMT1 positivity was found in majority of ROs and mi-

nority of chRCCs. PRMT1 might be an additional immunohistochemical

marker for differential diagnosis between ROs and chRCCs.

PS-25-003

The significance of intertubular growth and hilar soft tissue invasion

in pure seminomas

B. Hayit

, D. Turcan, M. F. Acikalin, C. Can

Eskisehir Osmangazi University, Pathology, Turkey

Objective:

To study the frequency of intertubular growth and hilar soft

tissue invasion (HSTI) in pure seminomas and analyze their association

with other clinicopathological predictors.

Method:

49 patients with pure seminoma diagnosed between 2002 and

2017 were assessed retrospectively. We evaluated age, tumour size,

lymphovascular invasion, tumour necrosis, intertubular growth,

intratubular germ cell neoplasia (ITGCN) and invasion into following

structures: tunica albuginea, epididymis, rete testis, hilar soft tissue.

Wednesday, 6 September 2017, 09:30

–

10:30, Hall 3

PS-25 Uropathology

Virchows Arch

(

2017

)

471

(

Suppl 1

–

S352

S264